AMLODIPINE-OLMESARTAN 10-40 MG

What it is

AMLODIPINE-OLMESARTAN 10-40 MG is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “amlodipine and olmesartan medoxomil”, “amlodipine besylate and olmesartan medoxomil” and “amlodipine besylate and olmesartran medoxomil”, as its NDCs’ listings variously write the nonproprietary name.

FDA gives its dosage form as “tablet” and “tablet, film coated” and its route as oral.

FDA lists 8 labelers (the companies named on the label) for its NDCs, among them Ajanta Pharma USA Inc., Camber Pharmaceuticals, Inc. and Macleods Pharmaceuticals Limited.

FDA lists it under 3 Established Pharmacologic Classes: Angiotensin 2 Receptor Blocker, Calcium Channel Blocker and Dihydropyridine Calcium Channel Blocker.

The NADAC file of 2026-10-14 prices it under 14 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $8.96 for 30 tablets (30 × $0.29874 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · Why 30 tablets · NADAC explanation codes

The 8 labelers

Other strengths, forms and brands

6 other products in the NADAC file share an FDA nonproprietary name with AMLODIPINE-OLMESARTAN 10-40 MG.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 14 NDCs’ NADAC prices is $0.29874 per EA filed.

Of the 107 other products in FDA’s Angiotensin 2 Receptor Blocker class priced per EA, 75 have a higher middle NADAC price and 32 a lower one. The one in the middle is OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-12.5, at $1.15137 per EA filed (eff. 2026-09-23).

Of the 107 other products in FDA’s Calcium Channel Blocker class priced per EA, 75 have a higher middle NADAC price and 32 a lower one. The one in the middle is DILTIAZEM 24H ER(LA) 240 MG TB, at $1.0087 per EA filed (eff. 2026-09-23).

Of the 67 other products in FDA’s Dihydropyridine Calcium Channel Blocker class priced per EA, 48 have a higher middle NADAC price and 19 a lower one. The one in the middle is ISRADIPINE 2.5 MG CAPSULE, at $1.13676 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $20.08 for 30 tablets, at an average of $0.66945 per EA in 2024 (2024-01-01 to 2024-12-31) for “Amlodipine-Olmesartan” and “Amlodipine Bes/Olmesartan Med”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 347,238 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

12 of the product’s 14 NDCs have this Medicare figure; the other 2 do not, and the interactive card says why for each.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.